Evidence map›Paper›PMID 40652336›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Nanomaterials Trigger Functional Anti-Tumoral Responses in Primary Human Immune Cells.

Vincent Mittelheisser, Olivier Lefebvre, Mainak Banerjee, Shayamita Ghosh, Amandine Dupas, Marie-Charlotte Diringer, Juliette Blumberger, Louis Bochler, Sébastien Harlepp, Annabel Larnicol and 11 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Nanomaterials Trigger Functional Anti-Tumoral Responses in Primary Human Immune Cells.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Vincent MittelheisserTumor Biomechanics lab, Strasbourg, 67000, France.ORCID https://orcid.org/0000-0002-0456-3957
Olivier LefebvreTumor Biomechanics lab, Strasbourg, 67000, France.ORCID https://orcid.org/0000-0001-9130-9174
Mainak BanerjeeÉquipe Labellisée Ligue Contre le Cancer, Strasbourg, 67000, France.ORCID https://orcid.org/0000-0001-9983-8222
Shayamita GhoshÉquipe Labellisée Ligue Contre le Cancer, Strasbourg, 67000, France.ORCID https://orcid.org/0000-0002-4315-4443
Amandine DupasTumor Biomechanics lab, Strasbourg, 67000, France.ORCID https://orcid.org/0009-0001-0846-6011
Marie-Charlotte DiringerÉquipe Labellisée Ligue Contre le Cancer, Strasbourg, 67000, France.
Juliette BlumbergerÉquipe Labellisée Ligue Contre le Cancer, Strasbourg, 67000, France.
Louis BochlerTumor Biomechanics lab, Strasbourg, 67000, France.ORCID https://orcid.org/0009-0003-7050-3287
Sébastien HarleppÉquipe Labellisée Ligue Contre le Cancer, Strasbourg, 67000, France.ORCID https://orcid.org/0000-0001-8891-7953
Annabel LarnicolTumor Biomechanics lab, Strasbourg, 67000, France.
Angélique PichotINSERM UMR_S1109, Strasbourg, 67000, France.ORCID https://orcid.org/0000-0003-2515-5538
Tristan StemmelenINSERM UMR_S1109, Strasbourg, 67000, France.ORCID https://orcid.org/0000-0002-4382-1277
Anne MolitorINSERM UMR_S1109, Strasbourg, 67000, France.ORCID https://orcid.org/0000-0003-1646-2325
Chloé MoritzLaboratoire de Spectrométrie de Masse BioOrganique (LSMBO), IPHC UMR 7178, CNRS, Université de Strasbourg, Infrastructure nationale ProFI FR 2048, Strasbourg, 67037, France.
Christine CarapitoLaboratoire de Spectrométrie de Masse BioOrganique (LSMBO), IPHC UMR 7178, CNRS, Université de Strasbourg, Infrastructure nationale ProFI FR 2048, Strasbourg, 67037, France.ORCID https://orcid.org/0000-0002-0079-319X
Raphaël CarapitoINSERM UMR_S1109, Strasbourg, 67000, France.ORCID https://orcid.org/0000-0002-7036-442X
Loïc J CharbonnièreInstitut Pluridisciplinaire Hubert Curien CNRS UMR 7178, Strasbourg, 67037, France.ORCID https://orcid.org/0000-0003-0328-9842
François LuxInstitut Lumière Matière, Université Claude Bernard - Lyon 1, CNRS UMR 5306, Villeurbanne, 69622, France.ORCID https://orcid.org/0000-0003-1568-0240
Olivier TillementInstitut Lumière Matière, Université Claude Bernard - Lyon 1, CNRS UMR 5306, Villeurbanne, 69622, France.ORCID https://orcid.org/0000-0001-7166-6537
Jacky G GoetzTumor Biomechanics lab, Strasbourg, 67000, France.ORCID https://orcid.org/0000-0003-2842-8116
Alexandre DetappeÉquipe Labellisée Ligue Contre le Cancer, Strasbourg, 67000, France.ORCID https://orcid.org/0000-0001-9364-1621

Funding

CNRS, the University of Strasbourg, the Agence National de la Recherche, the French Proteomics Infrastructure ANR-10-INBS-08-03CNRS, the University of Strasbourg, the Agence National de la Recherche, the French Proteomics Infrastructure ProFI FR2048Fondation ARC pour la recherche sur le cancer ARCDOC42023010006005HORIZON EUROPE European Research Council 950101IdEx Unistra ANR-10-IDEX-0002SFRI-STRAT'US ANR-20-SFRI-0012
6 · The paper itself

Abstract

Targeting the immune system with nanoparticles (NPs) to deliver immunomodulatory molecules emerged as a solution to address intra-tumoral immunosuppression and enhance therapeutic response. While the potential of nanoimmunotherapies in reactivating immune cells has been evaluated in several preclinical studies, the impact of drug-free nanomaterials on the immune system remains unknown. Here, the molecular and functional response of human NK cells and pan T cells to a selection of five NPs that are commonly used in biomedical applications are characterized. After a pre-screen to evaluate the toxicity of these nanomaterials on immune cells, ultrasmall silica-based gadolinium (Si-Gd) NPs and poly(lactic-co-glycolic acid) (PLGA) NPs are selected for further investigation. Bulk RNA-sequencing and flow cytometry analysis showcase that PLGA NPs trigger a transcriptional priming toward activation in NK and pan T cells. While PLGA NPs improved NK cells anti-tumoral functions in a cytokines-deprived environment, Si-Gd NPs significantly impaired T cells activation as well as functional responses to a polyclonal antigenic stimulation. Altogether, PLGA NPs are identified as an attractive strategy for reactivating the immune system of cancer patients.

Indexed as

Killer Cells, NaturalNanoparticlesNanostructuresNeoplasmsT-LymphocytesHumansImmunotherapyPolylactic Acid-Polyglycolic Acid CopolymerPolylactic Acid-Polyglycolic Acid Copolymerimmunotherapynanomaterialproteogenomics

Identifiers

PMID40652336
PMCPMC12533298

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.